

**SPECIFIC TESTS**• **PERCENT MONOMER**

**Mobile phase:** 34.84 mg/mL of arginine, 158.56 mg/mL of ammonium sulfate, and 100 mL/L of isopropyl alcohol in water. Adjust with phosphoric acid to a pH of 7.3, degas, and pass through a filter of 0.45- $\mu$ m pore size.

**System suitability solution:** 1 mg/mL each of chicken ovalbumin and bovine gamma globulin

**Standard solution:** 1 mg/mL of USP Alteplase RS in water

**Sample solution:** 1 mg/mL of Alteplase for Injection in water

**Chromatographic system**

(See *Chromatography* (621), *System Suitability*.)

**Mode:** LC

**Detector:** UV 280 nm

**Column:** 7.5-mm  $\times$  30-cm; packing L25

**Flow rate:** 0.5–1.0 mL/min

**Injection volume:** 50  $\mu$ L

**System suitability**

**Samples:** *System suitability solution* and *Standard solution*

**Suitability requirements**

**Resolution:** NLT 1.6 between gamma globulin and ovalbumin, *System suitability solution*

**Column efficiency:** NLT 1200 theoretical plates, determined from the alteplase peak, *Standard solution*

**Analysis**

**Sample:** *Sample solution*

Calculate, as a percentage, the monomer in the portion of Alteplase for Injection taken:

$$\text{Result} = (r_U/r_T) \times 100$$

$r_U$  = peak response of the alteplase monomer

$r_T$  = sum of all the peak responses related to alteplase

**Acceptance criteria:** NLT 95.0%

• **SINGLE-CHAIN CONTENT**

**Mobile phase:** 27.6 mg/mL of monobasic sodium phosphate in sodium dodecyl sulfate solution (1 in 1000). Adjust with sodium hydroxide to a pH of 6.8. Filter, and degas.

**Dithiothreitol solution:** 3.12 mg/mL of dithiothreitol in *Mobile phase*

**Standard stock solution:** Using an accurately weighed quantity of USP Alteplase RS, make a 1-mg/mL solution in water.

**Standard solution:** Pipet 1 mL of the *Standard stock solution* into a glass tube. Add 3 mL of *Dithiothreitol solution*, cap the tube, and invert to mix. Heat for 3–5 min at about 80°.

**Sample stock solution:** Using an accurately weighed quantity of Alteplase for Injection, make a 1-mg/mL solution in water.

**Sample solution:** Pipet 1 mL of the *Sample stock solution* into a glass tube. Add 3 mL of *Dithiothreitol solution*, cap the tube, and invert to mix. Heat for 3–5 min at about 80°.

**Chromatographic system**

(See *Chromatography* (621), *System Suitability*.)

**Mode:** LC

**Detector:** UV 214 nm

**Column:** 7.5-mm  $\times$  60-cm; packing L25

**Flow rate:** 0.5 mL/min

**Injection volume:** 50  $\mu$ L

**System suitability**

**Sample:** *Standard solution*

**Suitability requirements**

**Resolution:** NLT 1.1 between the single-chain and two-chain alteplase peaks

**Analysis**

**Samples:** *Standard solution* and *Sample solution*

[NOTE—The major peaks are from single-chain and two-chain alteplase and from higher and lower molecular weight species.]

Calculate the percentage of single-chain alteplase in the portion of Alteplase for Injection taken:

$$\text{Result} = (r_U/r_T) \times 100$$

$r_U$  = peak response for single-chain alteplase

$r_T$  = sum of all the peak responses of alteplase

**Acceptance criteria:** No peaks or shoulders in the *Sample solution* that are not present in the *Standard solution* are found; NLT 60%.

• **INJECTIONS AND IMPLANTED DRUG PRODUCTS (1):** Meets the requirements of constituted solutions at the time of use

• **PH (791)**

**Sample solution:** Constitute as directed in the labeling.

**Acceptance criteria:** 7.1–7.5

• **WATER DETERMINATION (921), Method I:** NMT 4.0%

• **BACTERIAL ENDOTOXINS TEST (85):** NMT 1 USP Endotoxin Unit/mg

• **STERILITY TESTS (71):** Meets the requirements when tested as directed in *Test for Sterility of the Product to Be Examined, Membrane Filtration*

• **BIOLOGICAL REACTIVITY TESTS, IN VIVO (88):** Meets the requirements for *Safety Tests—Biologicals*

**ADDITIONAL REQUIREMENTS**

• **PACKAGING AND STORAGE:** Preserve in hermetic, light-resistant containers, and store in a refrigerator.


• **LABELING:** Label it to state the biological activity in USP Alteplase Units/vial and the amount of protein/vial.

**Change to read:**

• **USP REFERENCE STANDARDS (11)**

USP Alteplase RS

• (CN 1–May-2018)

**Altretamine**

$C_9H_{18}N_6$  210.28  
1,3,5-Triazine-2,4,6-triamine, *N,N,N',N',N'',N''*-hexamethyl-; Hexamethylmelamine [645-05-6].

**DEFINITION**

Altretamine contains NLT 98.0% and NMT 102.0% of altretamine ( $C_9H_{18}N_6$ ), calculated on the anhydrous basis.

**IDENTIFICATION**

• **A. INFRARED ABSORPTION (197K)**

• **B.** The retention time of the major peak of the *Sample solution* corresponds to that of the *Standard solution*, as obtained in the Assay.

**ASSAY**

• **PROCEDURE**

**Buffer:** 0.79 g/L of ammonium carbonate in water. Adjust with a solution of formic acid (1 in 10) or ammonium hydroxide (1 in 10) to a pH of  $8.0 \pm 0.05$ .